Polaryx CEO Buys 88k Shares Amid Volatility, Signaling Undervalued Growth
CEO’s 88k share buy at $4.07 sparks debate over Polaryx’s undervaluation and future clinical milestones.
3 minutes to read
Polaryx Therapeutics Inc
Polaryx CFO Buys Shares Amid FDA “Safe to Proceed” Letter, Signaling Potential Upside for PLX‑200
Polaryx CFO’s insider buy signals confidence amid FDA “safe‑to‑proceed” letter and Phase‑2 trial; could boost value if PLX‑200 shows early efficacy.
4 minutes to read